Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A pilot study

A, Terraneo; L, Leggio; M, Saladini; M, Ermani; A, Bonci; L, Gallimberti
Abstract:
Recent animal studies demonstrate that compulsive cocaine seeking strongly reduces prelimbic frontal cortex activity, while optogenetic stimulation of this brain area significantly inhibits compulsive cocaine seeking, providing a strong rationale for applying brain stimulation to reduce cocaine consumption. Thus, we employed repetitive transcranial magnetic stimulation (rTMS), to test if dorsolateral prefrontal cortex (DLPFC) stimulation might prevent cocaine use in humans. Thirty-two cocaine-addicted patients were randomly assigned to either the experimental group (rTMS) on the left DLPFC, or to a control group (pharmacological agents) during a 29-day study (Stage 1). This was followed by a 63-day follow-up (Stage 2), during which all participants were offered rTMS treatment. Amongst the patients who completed Stage 1, 16 were in the rTMS group (100%) and 13 in the control group (81%). No significant adverse events were noted. During Stage 1, there were a significantly higher number of cocaine-free urine drug tests in the rTMS group compared to control (p=0.004). Craving for cocaine was also significantly lower in the rTMS group compared to the controls (p=0.038). Out of 13 patients who completed Stage 1 in the control group, 10 patients received rTMS treatment during Stage 2 and showed significant improvement with favorable outcomes becoming comparable to those of the rTMS group. The present preliminary findings support the safety of rTMS in cocaine-addicted patients, and suggest its potential therapeutic role for rTMS-driven PFC stimulation in reducing cocaine use, providing a strong rationale for developing larger placebo-controlled studies.
Patologie/Applicazioni:
Anno:
2016
Tipo di pubblicazione:
Articolo
Parola chiave:
dipendenze; corteccia prefrontale; stimolazione magnetica transcranica
Testata scientifica:
European Neuropsycopharmacology
DOI:
10.1016/j.euroneuro.2015.11.011
Hits: 2215

La nostra storia

GEA soluzioni si affaccia nel 2013 al mercato della strumentazione medicale di alto livello tecnologico ma la sua storia parte da più lontano, clicca qui per approfondire.  

GEA SOLUZIONI SRL
via Spalato 72/A, Torino
Tel.: 011 5821948 / 011 4463853
Fax: 011 0433281
Email: info @ geasoluzioni.it

P. IVA IT11696920013
REA TO1233648

EU-Cookies

Copyright © 2024 GEA SOLUZIONI SRL. Tutti i diritti riservati.

Search